Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)
NCT02375685 · Institut de Recherches Internationales Servier · PHASE3 · terminated · last registry update 2020-01-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Institut de Recherches Internationales Servier |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL1B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-12-17Results posted on the registry: Novartis Pharmaceuticals, ACZ885 + Placebo (NCT02961218)
- 2020-08-12Phase 3 first posted: University Hospital, Basel, Switzerland, Canakinumab + Placebo (NCT04510493)
- 2020-08-07Results posted on the registry: Charite University, Berlin, Germany, Canakinumab + Placebo (NCT02204293)
- 2020-08-07Also stopped (terminated): Charite University, Berlin, Germany, Canakinumab + Placebo (NCT02204293)
- 2020-06-11Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT02756650)
- 2020-05-19Results posted on the registry: Novartis Pharmaceuticals, canakinumab (NCT02334748)
- 2020-04-27Phase 3 first posted: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT04362813)
- 2020-03-16Results posted on the registry: Novartis Pharmaceuticals, ACZ885 + Placebo (NCT02888080)
- 2020-01-22Results posted on the registry: Novartis Pharmaceuticals, Canakinumab + Placebo (NCT01327846)
- 2020-01-14Phase 3 first posted: Pancreatic Cancer Action Network, Gemcitabine combined with nab-paclitaxel + Dose -mFOLFIRINOX (NCT04229004)
- 2020-01-03Also stopped (terminated): Institut de Recherches Internationales Servier, Gevokizumab + Placebo (NCT01965145)
- 2019-09-13Results posted on the registry: Novartis Pharmaceuticals, Canakinumab (NCT02396212)
- 2019-08-28Results posted on the registry: AbbVie, ABT-981 (NCT02087904)
- 2019-07-09Results posted on the registry: Novartis Pharmaceuticals, ACZ885 150 mg (Canakinumab) (NCT02296424)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision